Followers | 840 |
Posts | 120476 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
Sunday, April 19, 2015 6:21:53 PM
With Lovenox, there is variable animal feedstock, and hence you have to verify the batch production output indefinitely. The (purported) need for indefinite submissions to the FDA is what allowed Amphastar to succeed in Appellate Court by claiming non-infringement under the H-W Safe Harbor.
With Copaxone, on the other hand, there is no variable input element, so once you reverse-engineer TEVA’s (now also MNTA’s) production process, you’re done for all time and there is no need for ongoing submissions to the FDA.
Based on the interpretation of the Hatch-Waxman Safe Harbor taken by the CAFC, the above is a consequential distinction, IMO.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM